p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.

@article{Hardwick2018p53ReactiveTC,
  title={p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.},
  author={Nicola R. Hardwick and Paul Henry Frankel and Christopher Ruel and Julie Kilpatrick and Weimin Tsai and Ferdynand J Kos and Teodora I Kaltcheva and Lucille A. Leong and Robert Joseph Morgan and Vincent Chung and Raechelle Tinsley and Melissa Eng and Sharon Wilczynski and Joshua D. I. Ellenhorn and Don J Diamond and Mihaela C. Cristea},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2018},
  volume={24 6},
  pages={1315-1325}
}
Purpose: To conduct a phase I trial of a Modified Vaccinia Ankara vaccine delivering wild-type human p53 (p53MVA) in combination with gemcitabine chemotherapy in patients with platinum-resistant ovarian cancer.Experimental Design: Patients received gemcitabine on days 1 and 8 and p53MVA vaccine on day 15, during the first 3 cycles of chemotherapy. Toxicity was classified using the NCI Common Toxicity Criteria and clinical response assessed by CT scan. Peripheral blood samples were collected for… CONTINUE READING